Sign In
Buy WXXWY
$8.21
-0.700 (-7.86%)
At Close: Jun 03, 2026
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
08:30pm, Thursday, 09'th Oct 2025
SHANGHAI , Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ES
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has ach
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
12:00am, Tuesday, 23'rd Sep 2025
SHANGHAI , Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a c
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tibbi Cihaz Kurumu (TITCK)
12:00am, Wednesday, 17'th Sep 2025
WUXI, China , Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturi
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
09:30pm, Thursday, 11'th Sep 2025
SINGAPORE , Sept. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO o
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
05:00am, Thursday, 28'th Aug 2025
Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a healthier future SHAN
WuXi Biologics Reports Solid 2025 Interim Results
08:35am, Tuesday, 19'th Aug 2025
Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net p
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
05:00am, Tuesday, 12'th Aug 2025
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substan
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Sta
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
08:30pm, Wednesday, 06'th Aug 2025
Earns CDP's highest rating for supply chain engagement on climate Adds to other CDP recognition—Water Security A List and leadership score on climate change Drives sustainability through value chain
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
06:00am, Wednesday, 16'th Jul 2025
Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a health
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation sta
Focus: China pharma projects disrupted by Sino-US tensions
07:10pm, Tuesday, 17'th Jun 2025
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
06:10am, Monday, 09'th Jun 2025
The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L. It
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injecti
